A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer

Breast Cancer Research

Table 2 Risk of invasive breast cancer according to the HER2 Ile655Val polymorphism

Polymorphism	Cases		Controls		OR*	95% CI*	OR^†	95% CI^†
	N	%	N	%
All subjects
Ile/Ile	637	58.2	551	56.5	1 (Reference)		1 (Reference)
Ile/Val or Val/Val	457	41.8	425	43.5	0.92	0.76–1.10	0.90	0.75–1.09
Ile/Val	396	36.2	356	36.5	0.96	0.79–1.16	0.97	0.79–1.18
Val/Val	61	5.6	69	7.1	0.71	0.49–1.04	0.63	0.42–0.92
Localized disease^‡
Ile/Ile	425	58.5	551	56.5	1 (Reference)		1 (Reference)
Ile/Val or Val/Val	301	41.5	425	43.5	0.91	0.74–1.12	0.90	0.73–1.12
Ile/Val	257	35.4	356	36.5	0.94	0.76–1.16	0.95	0.76–1.19
Val/Val	44	6.1	69	7.1	0.78	0.52–1.18	0.69	0.45–1.06
Regional or distant metastasis^‡
Ile/Ile	195	57.5	551	56.5	1 (Reference)		1 (Reference)
Ile/Val or Val/Val	144	42.5	425	43.5	0.96	0.74–1.25	0.96	0.73–1.27
Ile/Val	128	37.8	356	36.5	1.03	0.79–1.36	1.08	0.81–1.44
Val/Val	16	4.7	69	7.1	0.60	0.34–1.09	0.49	0.26–0.90

*Logistic regression models conditional on age; ^†logistic regression models conditional on age and adjusted for family history of breast cancer, recent alcohol consumption, parity, menopausal status, age at menopause, hormone replacement therapy use, age at menarche, height at age 25 years, weight at age 18 years, and weight change since age 18 years; ^‡for cases at diagnosis. CI, confidence interval; OR, odds ratio.

ISSN: 1465-542X